Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566721 | 1.00 | DRD2 (0.53) | DRD2LTA4HADRA2AADRA2BADRA2C | |
| SCHEMBL567549 | 0.88 | DRD2 (0.55) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL567513 | 0.88 | DRD2 (0.55) | DRD2LTA4HADRA2AADRA2BADRA2C | |
| SCHEMBL30495467 | 0.88 | DRD2 (0.55) | DRD2LTA4HADRA2AADRA2BADRA2C | |
| SCHEMBL567512 | 0.88 | DRD2 (0.55) | DRD2LTA4HADRA2AADRA2BADRA2C | |
| SCHEMBL566712 | 0.88 | DRD2 (0.55) | DRD2ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL566797 | 0.88 | DRD2 (0.59) | DRD2LTA4HADRA2AADRA2BADRA2C | |
| SCHEMBL566798 | 0.88 | DRD2 (0.59) | DRD2LTA4HADRA2AADRA2BADRA2C | |
| SCHEMBL30495418 | 0.88 | DRD2 (0.59) | DRD2LTA4HADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL31137875 | 0.87 | DRD2 (0.54) | DRD2LTA4HADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4460298-A1 | Alpha2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-11-13 | — | — | EP | claimed |
| CN-118785902-A | Alpha 2-adrenoceptor subtype C antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2023131640-A1 | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4460298-A1 | Alpha2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-11-13 | — | — | EP | disclosed |
| CN-118785902-A | Alpha 2-adrenoceptor subtype C antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2023131640-A1 | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-13 | — | — | WO | disclosed |